Procter & Gamble NYSE:PG Once again, it’s proven that this is not a game for investors, but a solid company that can increase its shareholder value over time. The share price may retreat and the market may experience volatility, but it is above trend and the chart shows a signal that followed trends in early 2025. The FQ2 2025 earnings report triggered a signal that could lead to a new everything. Time this year. Regardless of when a new high is set, a new high is likely, and until then there are capital returns to keep the market interested.
Procter & Gamble today
Procter & Gamble
- 52 week range
- $152.06
▼
$180.43
- Dividend yield
- 2.45%
- P/E ratio.
- 26.18
- VALUE VALUE
- $180.53
Share repurchases are not foolproof, but are sufficient to offset the dilution and reduce the number gradually each quarter. Buyers in FQ2 totaled $2.5 billion, doubling the $2.4 billion spent on dividend distributions, reducing the bill by about 0.4%. In terms of dividends, the stock is yielding about 2.5% in mid-January, at the high end of its historical range and value for investors. The stock is trading at about 24 times, compared to the historical average of 28 times, suggesting that upside price action could be vigorous. The 4x multiple expansion to match the 10-year average represents over 16% growth in addition to the dividend distribution and an attractive return for any dividend investor.
The analyst’s setup and trends are consistent with higher price prospects for PG stock. The trend includes increased coverage and price target compared to January 2024. The consensus figure is up nearly 800 basis points and indicates an 8% increase from the critical 30-day EMA on issue day. The most recent activity includes trimming the funds’ price target to match consensus, a headwind that is likely to fade now with Q2 results. Field
Procter & Gamble Outperforms in FQ2, Cautiously Confirms 2025 Guidance
Procter & Gamble didn’t have a solid second quarter, but the data is good and signals strength for consumers and retailers across many segments. The company’s revenue is $21.9 billion. The US rose 2.1% year-over-year, $0.310 better than the consensus reported by Marketbeat. The 140 basis points of strength are associated with a 3% organic gain, driven by a 2% increase in volume and a 1% increase in mixture. Prices did not affect the results, revealing a solid consumer base. Beauty grew the least amount, up 2% organically, with baby, women’s and family care leading at +4%. Family Care was the strongest performer in the BFF segment, with double-digit quarterly sales growth.
Procter & Gamble dividend payments
- Dividend yield
- 2.45%
- Annual dividend
- $4.03
- Dividend increases track record
- 36 years old
- Annual dividend growth 3-year
- 5.21%
- Dividend payout ratio
- 64.17%
- Next dividend payment
- February 18
PG Dividend History
Margin News is also good. The company experienced margin pressure, but efforts to control costs and improve efficiency offset it by 260 basis points. The net result was a basis point decline in core operating margin and $1.88 in adjusted earnings, up 2% versus a 2.1% increase in revenue and $0.02 ahead of forecasts.
The forecast for this year is decent. The company did not raise management but reiterated its earnings growth outlook. The critical takeaway is that the adjusted range of $6.91 to $7.05 has a midpoint above the consensus outlook and is favorable for the market. Ultimately, the return of capital forecast is confirmed, including an increase in distribution. Procter & Gamble is a dividend aristocrat and dividend king that pays less than 60% of its earnings and is able to maintain average earnings. The outlook is for 5% to 6% EPS growth in 2025, with a slight acceleration in 2026.
Procter & Gamble fires trend signal
Following the Q2 release, Procter & Gamble shares rose 3% to confirm support above the uptrend line and long-term moving average. The move also puts the market above another critical moving average, the 30-day EMA, which is suggesting buying among short-term traders and speculators. The movement appears strong due to the increase in volume; The likely outcome is a move to retest resistance at recent highs. Critical resistance is around $180 to $185 and could be reached before mid-year.
Before you consider Procter & Gamble, you’ll want to hear this.
Marketbeat tracks the top and best-performing analysts with top-performing Wall Street analysts and the stocks they recommend to their clients daily. Marketbeat has identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market takes over… and Procter & Gamble wasn’t on the list.
While Procter & Gamble currently has a Moderate Buy rating among analysts, the top-rated analysts consider these five stocks to be Outperform Buys.
View five stocks here
What stocks are the top institutional investors, including hedge funds and endowments, buying in today’s market? Click the link below and we’ll send you Marketbeat’s list of thirteen stocks that institutional investors are buying the fastest.
Get this free report